14 July 2016

Avacta and Glythera partner to develop alternative ADC

Avacta Group PLC said on Thursday it would collaborate with Glythera Ltd to develop a new, highly targeted bio-therapeutics as an alternative to established antibody drug conjugates. The company said the combined potential benefits of the collaboration could create a new leading antibody drug conjugate, with a number of benefits over current products. Avacta said their Affimer-drug technology could improve tumour penetration, while Glythera's PermaLink technology could reduce toxicity effects. Source: London & SE News 14/7/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).